CONSORT Med PLC/S (OTCMKTS: CSRMY) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.
CONSORT Med PLC/S pays an annual dividend of $0.24 per share and has a dividend yield of 1.7%. Sientra does not pay a dividend. CONSORT Med PLC/S pays out 28.9% of its earnings in the form of a dividend.
CONSORT Med PLC/S has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Sientra has a beta of -0.92, suggesting that its stock price is 192% less volatile than the S&P 500.
Institutional and Insider Ownership
59.1% of Sientra shares are owned by institutional investors. 31.0% of Sientra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares CONSORT Med PLC/S and Sientra’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CONSORT Med PLC/S||$380.46 million||1.86||$29.23 million||$0.83||17.34|
|Sientra||$36.54 million||15.75||-$64.02 million||($2.82)||-7.24|
CONSORT Med PLC/S has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than CONSORT Med PLC/S, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings for CONSORT Med PLC/S and Sientra, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|CONSORT Med PLC/S||0||0||0||0||N/A|
Sientra has a consensus target price of $18.20, suggesting a potential downside of 10.87%. Given Sientra’s higher probable upside, analysts clearly believe Sientra is more favorable than CONSORT Med PLC/S.
This table compares CONSORT Med PLC/S and Sientra’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|CONSORT Med PLC/S||N/A||N/A||N/A|
CONSORT Med PLC/S beats Sientra on 9 of the 15 factors compared between the two stocks.
About CONSORT Med PLC/S
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients and finished dose drugs. Consort Medical plc was incorporated in 1946 and is based in Hemel Hempstead, the United Kingdom.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Receive News & Ratings for CONSORT Med PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONSORT Med PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.